Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study of ANV/3TC/TDF versus BIC/FTC/TAF in virologically suppressed treatment-experienced adults with HIV-1
ChiCTR2400082475Phase 4Not yet recruiting
- Sponsor
- The Sixth People's Hospital of Zhengzhou
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Human immunodeficiency virus infection type 1 comparing ANV/3TC/TDF group with BIC/FTC/TAF group (2 arms). Primary endpoints: Proportion of patients with undetectable HIV RNA at 48 weeks and Change in blood lipids from baseline at 48 weeks. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
ainuovirinelamivudinetenofovir disoproxil fumaratebictegraviremtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ChiCTR2400082475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082475.